3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
3
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
92
Nivolumab
57
Cyclophosphamide
22
Ipilimumab
17
atezolizumab
15
Magnetic Resonance Spectroscopy
14
Specimen Handling
13
Radiosurgery
13
Paclitaxel
13
Interleukin-2
12
Docetaxel
12
fludarabine
11
Carboplatin
11
Pemetrexed
10
spartalizumab
9
Biopsy
9
durvalumab
8
Cisplatin
8
Radiotherapy
7
Immune Checkpoint Inhibitors
7
Blood Specimen Collection
7
cemiplimab
6
avelumab
6
aldesleukin
6
Taxes
6
Gemcitabine
6
Drug Therapy
6
Bevacizumab
6
trametinib
5
tislelizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Desflurane
×
Thoracic
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled